OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation, Inc. (OTCBB:ISCO) announced today that its wholly owned subsidiary, Lifeline Cell Technology, LLC, has entered into a research agreement with the Regents of the University of California for three studies, one of which is focused on stem cell therapy for the possible treatment of macular degeneration and retinitis pigmentosa.
